Ras, PI(3)K and mTOR signalling controls tumour cell growth
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
All eukaryotic cells coordinate cell growth with the availability of nutrients in their environment. The mTOR protein kinase has emerged as a critical growth-control node, receiving stimulatory signals from Ras and phosphatidylinositol-3-OH kinase (PI(3)K) downstream from growth factors, as well as nutrient inputs in the form of amino-acid, glucose and oxygen availability. Notably, components of the Ras and PI(3)K signalling pathways are mutated in most human cancers. The preponderance of mutations in these interconnected pathways suggests that the loss of growth-control checkpoints and promotion of cell survival in nutrient-limited conditions may be an obligate event in tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
From Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth (2008) · cites this paper as [13]
In the citing paper
“PI3K signaling may be central to linking the common genetic perturbations of cancer, such as RTK mutations and PTEN loss, with altered metabolic processes, including the “lipogenic phenotype” common to many cancers, including GBM (13, 14, 17, 20).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [20]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 8×
“So, the PI(3)K heterodimer is recruited to the membrane to generate local pools of PtdIns(3,4,5)P3.”
BackgroundInfluentialAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914 · cited 1×
“AMPK inhibits mTOR at least in part by the direct phosphorylation of tuberin ( Box 3 ), and cells that lack tuberin retain activated mTORC1 under conditions of low glucose as well as hypoxi”
BackgroundRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 1×
“In addition to loss of RasGAP function, Ras activity is reported to be elevated through reduced expression of a conserved microRNA (let-7) that targets the 3′ untranslated region of H-ras, N-ras and K-ras messenger RNA”
BackgroundHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · cited 1×
“PTEN catalyses removal of the D3 phosphate from PtdIns(3,4,5)P 3 (the reverse of the reaction catalysed by PI(3)K) to limit and ultimately terminate PI(3)K signalling in cell”
BackgroundSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“The existence of the S6K-based negative-feedback loop means that prolonged rapamycin treatment will probably lead to enhanced PI(3)K–AKT activation in some tumours, as has been observed in several tumour cell lines grown in culture, and in tissues from patients in clinical trials of rapamycin analogue”
Background
Cited by
Items 401–500 of 1,006
Noninvasive molecular biomarkers for the detection of colorectal cancer
Kim, H. J., Yu, M., Kim, H., Byun, J., & Lee, C. (2008) · BMB Reports · doi:10.5483/bmbrep.2008.41.10.685 · Cited by 108
mRNA Translation and Energy Metabolism in Cancer: The Role of the MAPK and mTORC1 Pathways
Topisirovic, I., & Sonenberg, N. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010785 · Cited by 92
Evolving role of adiponectin in cancer-controversies and update
Katira, A., & Tan, P. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2015.0092 · Cited by 102
Regulators of glucose uptake in thyroid cancer cell lines
Heydarzadeh, S., Moshtaghie, A. A., Daneshpoor, M. S., & Hedayati, M. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00586-x · Cited by 102
“which results in increased glycolysis flux [51, 105].”
Heinrich, F., & Lösche, M. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.03.007 · Cited by 104
Eddy, J. A., Hood, L., Price, N. D., & Geman, D. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000792 · Cited by 96
“Research has linked modulated function on the level of either metabolic networks [7-9] and/or signaling networks [10-12] to cancer hallmarks including angiogenesis,”
BackgroundTumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression.
Kechagioglou, P., Papi, R. M., Provatopoulou, X., Kalogera, E., Papadimitriou, E., Grigoropoulos, P., Nonni, A., Zografos, G., Kyriakidis, D. A., & Gounaris, A. (2014) · PubMed · Cited by 95
Chamcheu, J. C., Adhami, V. M., Esnault, S. J., Sechi, M., Siddiqui, I. A., Satyshur, K. A., Syed, D. N., Dodwad, S.-J. M., Chaves-Rodriquez, M.-I., Longley, B. J., et al. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6769 · Cited by 103
“This resistance has been partially ascribed to a feedback loop that triggers Akt activation via p70S6K inhibition (33, 37, 44).”
Houédé, N., & Pourquier, P. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.06.004 · Cited by 98
“…(Bartholomeusz & Gonzalez-Angulo, 2012; Courtney, Corcoran, & Engelman, 2010; Knowles, Platt, Ross, & Hurst, 2009; McCubrey, Steelman, Chappell, Abrams, Franklin, et al., 2012; McCubrey, Steelman, Chappell, Abrams, Montalto, et al., 2012; Populo, Lopes, & Soares, 2012; Shaw & Cantley, 2006).”
Jing, H., Zhou, X., Dong, X., Cao, J., Zhu, H., Lou, J.-S., Hu, Y., He, Q., & Yang, B. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.01.035 · Cited by 98
Hafner, C. M., Toll, A., Fernández-Casado, A., Earl, J., Marqués, M., Acquadro, F., Méndez‐Pertuz, M., Urioste, M., Malats, N., Burns, J. E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008365107 · Cited by 100
Lu, Z. H., Shvartsman, M. B., Lee, A. Y., Shao, J. M., Murray, M. M., Kladney, R. D., Fan, D., Krajewski, S., Chiang, G. G., Mills, G. B., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3467 · Cited by 92
Multifaceted roles of Adiponectin in cancer
Hebbard, L., & Ranscht, B. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.11.005 · Cited by 103
Smith, E. D., Prieto, G. A., Tong, L., Sears-Kraxberger, I., Rice, J. D., Steward, O., & Cotman, C. W. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.568659 · Cited by 90
Bohnacker, T., Marone, R., Collmann, E., Calvez, R., Hirsch, E., & Wymann, M. P. (2009) · Science Signaling · doi:10.1126/scisignal.2000259 · Cited by 90
Size control: the developmental physiology of body and organ size regulation
Gokhale, R. H., & Shingleton, A. W. (2015) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.181 · Cited by 108
Calay, D., Vind-Kezunovic, D., Frankart, A., Lambert, S., Poumay, Y., & Gniadecki, R. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.415 · Cited by 99
“Several studies have shown that Akt/protein kinase B is a cardinal regulator of cell survival and its pathological increase in activity causes carcinogenesis (Datta et al., 1999; Shaw and Cantley, 2006).”
BackgroundFrontier of Epilepsy Research - mTOR signaling pathway
Cho, C.-H. (2011) · Experimental and Molecular Medicine · doi:10.3858/emm.2011.43.5.032 · Cited by 93
Martinelli, E., Troiani, T., D'Aiuto, E., Morgillo, F., Vitagliano, D., Capasso, A., Costantino, S., Ciuffreda, L. P., Merolla, F., Vecchione, L., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28236 · Cited by 92
Origin and Therapies of Osteosarcoma
Moukengué, B., Lallier, M., Marchandet, L., Baud’huin, M., Verrecchia, F., Ory, B., & Lamoureux, F. (2022) · Cancers · doi:10.3390/cancers14143503 · Cited by 102
“mTOR is a serine/threonine kinase involved in the deregulated PI3K/Akt pathway in most cancers [279,280].”
RAS: Target for Cancer Therapy
Saxena, N., Lahiri, S. S., Hambarde, S., & Tripathi, R. P. (2008) · Cancer Investigation · doi:10.1080/07357900802087275 · Cited by 92
“Moreover, several other human cancer harbors alteration in factors that lie upstream of RAS, leading to over expression or mutational activation of growth factor receptor tyrosine kinase, such as epidermal growth factor (EGFR and ERBB2), or downstream of RAS, such as mutation of B-Raf in melanomas (5, 28).”
BackgroundMetformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells
Klubo-Gwiezdzinska, J., Jensen, K., Costello, J., Patel, A., Hoperia, V., Bauer, A., Burman, K. D., Wartofsky, L., & Vasko, V. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-12-0046 · Cited by 87
“In addition to being directly phosphorylated by AKT, TSC2 can be phosphorylated and inactivated by ERK as well as its downstream kinase RSK (Shaw & Cantley 2006).”
BackgroundShen, C., Oswald, D. J., Phelps, D. A., Çam, H., Pelloski, C. E., Pang, Q., & Houghton, P. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4282 · Cited by 95
Distinct functions of HTLV-1 Tax1 from HTLV-2 Tax2 contribute key roles to viral pathogenesis
Higuchi, M., & Fujii, M. (2009) · Retrovirology · doi:10.1186/1742-4690-6-117 · Cited by 86
“The mammalian target of rapamycin (mTOR) is one of the crucial downstream targets of Akt which is used to promote cell survival and growth mainly through the stimulation of translational initiation [128].”
BackgroundSalivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations
Luk, P. P., Weston, J. D., Yu, B., Selinger, C. I., Ekmejian, R., Eviston, T. J., Lum, T., Gao, K., Boyer, M. J., O'Toole, S. A., et al. (2015) · Head & Neck · doi:10.1002/hed.24332 · Cited by 92
“PIK3CA, NRAS, HRAS, and AKT1 share a common signaling pathway with HER2 and other tyrosine kinase receptors.(38) This implies that the HER2/RAS/AKT signaling axis is important for oncogenesis in a subset of salivary duct carcinoma and targeting of downstream effectors may provide a viable therapeutic option.”
BackgroundTranslation factors and ribosomal proteins control tumor onset and progression: how?
Loreni, F., Mancino, M., & Biffo, S. (2013) · Oncogene · doi:10.1038/onc.2013.153 · Cited by 103
Ducker, G. S., Atreya, C. E., Simko, J. P., Hom, Y. K., Matli, M. R., Benes, C. H., Hann, B. C., Nakakura, E. K., Bergsland, E. K., Donner, D. B., et al. (2013) · Oncogene · doi:10.1038/onc.2013.92 · Cited by 101
“12 Enhanced response to mTOR inhibition in patients with rare somatic tuberous sclerosis complex mutations supports the rationale of targeting this network.”
Nucera, C., Nehs, M. A., Nagarkatti, S. S., Sadow, P. M., Mekel, M., Fischer, A. H., Lin, P. S., Bollag, G. E., Lawler, J., Hodin, R. A., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0317 · Cited by 92
Khorasani, A. B. S., Pourbagheri‐Sigaroodi, A., Pirsalehi, A., Safaroghli‐Azar, A., Zali, M. R., & Bashash, D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173983 · Cited by 94
D'Amato, V., Rosa, R., D’Amato, C., Formisano, L., Marciano, R., Nappi, L., Raimondo, L., Mauro, C. D., Servetto, A., Fusciello, C., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.241 · Cited by 94
“The mammalian target of rapamycin is a highly conserved serine/threonine kinase downstream of the PI3K/AKT pathway; it has a crucial role in tumorigenesis (Guertin and Sabatini, 2007) and its inhibition could prevent cancer cell proliferation (Engelman et al, 2006; Shaw and Cantley, 2006; Yuan and Cantley, 2008).”
BackgroundRas drives malignancy through stem cell crosstalk with the microenvironment
Yuan, S., Stewart, K. S., Yang, Y., Abdusselamoglu, M. D., Parigi, S. M., Feinberg, T. Y., Tumaneng, K., Yang, H., Levorse, J. M., Polak, L., et al. (2022) · Nature · doi:10.1038/s41586-022-05475-6 · Cited by 94
Stanford, M. M., Barrett, J. W., Nazarian, S. H., Werden, S. J., & McFadden, G. (2006) · Journal of Virology · doi:10.1128/jvi.01408-06 · Cited by 97
“The MV-promoting effects of rapamycin can be attributed at least in part to its ability to activate Akt phosphorylation (42), likely due to an S6K-based feedback upregulation mechanism (49).”
BackgroundCengel, K. A., Voong, K. R., Chandrasekaran, S., Maggiorella, L., Brunner, T. B., Stanbridge, E. J., Kao, G. D., McKenna, W. G., & Bernhard, E. J. (2007) · Neoplasia · doi:10.1593/neo.06823 · Cited by 90
“[1]).”
Yang, S.-H., Li, W., Sumien, N., Forster, M. J., Simpkins, J. W., & Liu, R. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.005 · Cited by 94
“The PI3K/Akt/mTOR signaling has long been recognized as a key pathway downstream of growth factor receptor tyrosine kinase that is involved in cancer cells survival, growth, and metabolism (Cantley, 2002; Shaw and Cantley, 2006).”
BackgroundSmith, M. C., Mader, M. M., Cook, J. A., Iversen, P. W., Ajamie, R. T., Perkins, E. J., Bloem, L. J., Yip, Y. Y., Barda, D. A., Waid, P. P., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0996 · Cited by 95
“The most common activating alteration is loss of the tumor suppressor PTEN through gene deletion or inactivating mutation [17-19].”
Shukla, S., Patric, I. R. P., Patil, V., Shwetha, S. D., Hegde, A. S., Chandramouli, B. A., Arivazhagan, A., Santosh, V., & Somasundaram, K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.567032 · Cited by 88
“However, mTOR(the inhibitor of Atg1 complex), which is constitutively activated by the PI3 kinase-Akt cascade in many cancers because of multiple upstream signaling from various tyrosine kinases as well as inactivation of inhibitors of this pathway, which include PTEN, AMPK, and TSC1/TSC2, can effectively inhibit auto…”
BackgroundMolecular damage in cancer: an argument for mTOR-driven aging
Blagosklonny, M. V. (2011) · Aging · doi:10.18632/aging.100422 · Cited by 90
“The PI3K/mTOR pathway is universally involved in cancer [37, 165-180].”
BackgroundSun, X., Han, L., Seth, P., Bian, S., Li, L., Csizmadia, E., Junger, W. G., Schmelzle, M., Usheva, A., Tapper, E. B., et al. (2013) · Hepatology · doi:10.1002/hep.25989 · Cited by 87
“More specifically, in these settings, Ras and phosphatidylinositol-3-OH kinase (PI3K) pathways converge to activate mTOR in response to nutrients and to mitogens.(2) The role of purinergic signaling(3,4) in hepatocarcinogenesis is unexplored.”
BackgroundCohen, L., Sekler, I., & Hershfinkel, M. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.262 · Cited by 90
“It is commonly accepted that mTORC1 is activated through the PI3K/AKT pathway, but there are also studies suggesting that growth factors signal to mTORC1 complexes also through the ERK pathway.(49) Owing to its major role in colonocytes growth, mTOR silencing was suggested as a therapeutic strategy for colorectal canc…”
BackgroundThe Regulation of Aging and Longevity: A New and Complex Role of p53
Feng, Z., Lin, M., & Wu, R. (2011) · Genes & Cancer · doi:10.1177/1947601911410223 · Cited by 89
“AKT phosphorylates and regulates several cellular proteins, including FOXO transcription factors, BAD, MDM2, and GSK3α/β, to facilitate cell survival and cell cycle entry.(38,39) The FOXO proteins play an important role in longevity regulation.”
BackgroundSaurat, T., Buron, F., Rodrigues, N., de Tauzia, M.-L., Colliandre, L., Bourg, S., Bonnet, P., Guillaumet, G., Akssira, M., Corlu, A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401138v · Cited by 90
Kaufman, J. M., Amann, J. M., Park, K., Arasada, R. R., Li, H., Shyr, Y., & Carbone, D. P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000173 · Cited by 87
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
Roncolato, F. T., Lindemann, K. Y., Willson, M. L., Martyn, J. K., & Mileshkin, L. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012160.pub2 · Cited by 109
“How the intervention might work The PI3K/AKT/mTOR pathway is involved in the development of EC (Shaw 2006).”
BackgroundInfluentialThe acetyl-CoA carboxylase enzyme: a target for cancer therapy?
Wang, C., Ma, J., Zhang, N., Yang, Q., Jin, Y., & Wang, Y. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1038246 · Cited by 88
“Uddin S, Siraj AK, Al-Rasheed M, et al. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers.”
BackgroundTargeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance
McCubrey, J. A., Steelman, L. S., Franklin, R. A., Abrams, S. L., Chappell, W. H., Wong, E. W. T., Lehmann, B. D., Terrian, D. M., Bäsecke, J., Stivala, F., et al. (2007) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2006.12.013 · Cited by 97
mTOR-Dependent Cell Proliferation in the Brain
Ryskalin, L., Lazzeri, G., Flaibani, M., Biagioni, F., Gambardella, S., Frati, A., & Fornai, F. (2017) · BioMed Research International · doi:10.1155/2017/7082696 · Cited by 86
“Over the past decades, Akt-mTOR signaling has increasingly garnered a central role in regulating several molecular and biochemical pathways which are known to be altered in a variety of pathological conditions encompassing obesity, cardiovascular diseases, hypertension, type II diabetes, neurodegeneration, and brain t…”
BackgroundAkt activation enhances ribosomal RNA synthesis through casein kinase II and TIF-IA
Nguyen, L. X. T., & Mitchell, B. S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313097110 · Cited by 96
“Although cellular transformation has been most frequently related to the dysregulation of protein translation as a consequence of mTOR activation (35, 36), the role of Akt in enhancing ribosomal biogenesis is receiving increasing attention (3, 37).”
BackgroundMisra, U. K., & Pizzo, S. V. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.2.10422 · Cited by 92
“Here we show that incubation of 1-LN cells with anti-CTD antibody either alone or before α 2 M* treatment significantly elevated levels of PUMA, NOXA, BID and BIK compared to cells treated with α 2 M* alone by PTEN whose expression is inversely related to that of phosphorylated Akt in cancer cells.(25-28) Loss of PTEN…”
BackgroundInfluentialEndoplasmic reticulum is a main localization site of mTORC2
Boulbés, D. R., Shaiken, T. E., & Sarbassov, D. D. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.08.034 · Cited by 96
“Growth factor peptides regulate cell growth, proliferation, survival, and metabolism by activation of the phosphatidylinositol-3-OH kinase (PI3K)/Akt pathway [1].”
BackgroundWorster, D. T., Schmelzle, T., Solimini, N. L., Lightcap, E. S., Millard, B., Mills, G. B., Brugge, J. S., & Albeck, J. G. (2012) · Science Signaling · doi:10.1126/scisignal.2001986 · Cited by 83
“Both pathways are involved in the activation of the kinase mTOR (mammalian TOR, which controls the rate of cellular growth by promoting protein translation) (3), c-Myc (a key transcription factor controlling both metabolism and cell cycle progression) (4), and cyclin D (a central regulator of the transition from G1 to…”
BackgroundEnergy Restriction as an Antitumor Target of Thiazolidinediones
Wei, S., Kulp, S. K., & Chen, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.065466 · Cited by 89
Wang, X., Hawk, N. N., Yue, P., Kauh, J. S. W., Ramalingam, S. S., Fu, H., Khuri, F. R., & Sun, S. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.12.6944 · Cited by 92
PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects
Krymskaya, V. P., & Goncharova, E. A. (2009) · Cell Cycle · doi:10.4161/cc.8.3.7555 · Cited by 86
Zhang, C., Yuan, X., Li, H., Zhao, Z.-J., Liao, Y., Wang, X.-Y., Su, J., Sang, S., & Liu, Q. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000369707 · Cited by 88
Li, C., Li, X., Liu, S.-F., Qu, W., Wang, W., & Tian, D. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.03.001 · Cited by 93
“Nevertheless, it will be necessary to carefully examine the effects of mTOR blockade on formation of glial scar and functional recovery in vivo after CNS disorders such as SCI and cerebral ischemia because of the complexities of mTOR pathway and its importance in regulating the physiology of different cell types in th…”
BackgroundNon-apoptotic cell death associated with perturbations of macropinocytosis
Maltese, W. A., & Overmeyer, J. H. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00038 · Cited by 86
“However, it is well established that LAMP1 can be detected on nonlysosomal compartments, such as late endosomes and late-stage macropinosomes (Humphries et al., 2011; Egami and Araki, 2012; Pols et al., 2013).”
BackgroundmTORC1‐ and mTORC2‐interacting proteins keep their multifunctional partners focused
Bracho‐Valdés, I., Moreno‐Alvarez, P., Valencia‐Martínez, I., Robles‐Molina, E., Chávez‐Vargas, L., & Vázquez‐Prado, J. (2011) · IUBMB Life · doi:10.1002/iub.558 · Cited by 89
The autophagy conundrum in cancer: influence of tumorigenic metabolic reprogramming
Eng, C. H., & Abraham, R. T. (2011) · Oncogene · doi:10.1038/onc.2011.220 · Cited by 85
Targeting mTOR pathway: A new concept in cancer therapy
Advani, S. H. (2010) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/0971-5851.76197 · Cited by 96
“134 Indian Journal of Medical and Paediatric Oncology | Oct-Dec 2010 | Vol 31 | Issue 4 that contribute to tumor progression.[15]”
BackgroundZhu, B., Zhou, Y., Xu, F., Shuai, J., Li, X., & Fang, W. (2012) · Journal of Virology · doi:10.1128/jvi.01434-12 · Cited by 86
“ERK1/2 has been found to inhibit TSC2 in vitro and in vivo (33, 50).”
BackgroundPhosphoinositide phosphatases in a network of signalling reactions
Bléro, D., Payrastre, B., Schurmans, S., & Erneux, C. (2007) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-007-0304-5 · Cited by 93
“This lipid is required for the recruitment and activation of several protein kinases, such as the phosphoinositide-dependent protein kinases and protein kinase B (PKB) and is critically involved in major human diseases such as diabetes and cancer [115].”
Wang, Z., Huang, Y., & Zhang, J. (2014) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-014-0191-7 · Cited by 85
Steinbrunn, T., Stühmer, T., Gattenlöhner, S., Rosenwald, A., Mottok, A., Unzicker, C., Einsele, H., Chatterjee, M., & Bargou, R. C. (2011) · Blood · doi:10.1182/blood-2010-05-284422 · Cited by 81
Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
Domvri, K., Zarogoulidis, P., Darwiche, K., Browning, R. F., Jr., Li, Q., Turner, J. F., Kioumis, I. P., Spyratos, D., Porpodis, Κ., Papaiwannou, A., et al. (2013) · Journal of Cancer · doi:10.7150/jca.7734 · Cited by 87
“This EGFR family activates two major downstream intracellular pathways in solid tumors, the RAS/RAF/MEK/MARK and the PI3K/AKT/ mTOR pathway, which induce cancer cell proliferation, cell growth, invasion, metastatic spread, apoptosis, and tumor angiogenesis [29].”
BackgroundSynthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer
Hu, Y., & Guo, M. (2020) · Cancer Science · doi:10.1111/cas.14565 · Cited by 92
Piguet, A., Semela, D., Keogh, A., Wilkens, L., Stroka, D., Stoupis, C. A., St–Pierre, M. V., & Dufour, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.03.024 · Cited by 82
Seitz, C. M., Hugle, M., Cristofanon, S., Tchoghandjian, A., & Fulda, S. (2012) · International Journal of Cancer · doi:10.1002/ijc.27935 · Cited by 95
“The phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway integrates survival signals provided by extracellular and intracellular stimuli to promote cell growth and to inhibit cell death.(7,8) Furthermore, the PI3K/Akt/mTOR pathway is involved in the control of autophagy, an ubiquitous…”
BackgroundA 2009 Update on the Treatment of Patients with Hormone Receptor—Positive Breast Cancer
Cleator, S. J., Ahamed, E., Coombes, R. C., & Palmieri, C. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.001 · Cited by 82
Guglielmotto, M., Tamagno, E., & Danni, O. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.93 · Cited by 82
An evolutionary perspective of AMPK–TOR signaling in the three domains of life
Roustan, V., Jain, A., Teige, M., Ebersberger, I., & Weckwerth, W. (2016) · Journal of Experimental Botany · doi:10.1093/jxb/erw211 · Cited by 88
Wu, R. P., Murali, R., Kabe, Y., French, S. W., Chiang, Y., Liu, S., Sher, L. S., Wang, C. C. C., Louie, S. G., & Tsukamoto, H. (2018) · Hepatology · doi:10.1002/hep.30071 · Cited by 85
“(8,9) The mammalian Target of Rapamycin (mTOR) pathway is one of the most well studied pathways in cancer, as it often is activated in tumors including HCC.(10,11) Indeed, activation of mTOR pathway in transgenic (Tg) mice(12) is sufficient to cause HCC.”
BackgroundDehnhardt, C. M., Venkatesan, A. M., Santos, E. D., Chen, Z., dos Santos, O., Ayral‐Kaloustian, S., Brooijmans, N., Mallon, R. G., Hollander, I. J., Feldberg, L. R., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9014982 · Cited by 85
Oncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors
Haferkamp, S., Scurr, L. L., Becker, T. M., Frausto, M., Kefford, R. F., & Rizos, H. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.5 · Cited by 93
Yoon, S.-O., Shin, S., Liu, Y., Ballif, B. A., Woo, M. S., Gygi, S. P., & Blenis, J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.024 · Cited by 86
Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer
Nakabayashi, M., Werner, L., Courtney, K. D., Buckle, G. C., Oh, W. K., Bubley, G. J., Hayes, J. H., Weckstein, D. J., Elfiky, A. A., Sims, D. M., et al. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11456.x · Cited by 82
Myxoma Virus Oncolysis of Primary and Metastatic B16F10 Mouse Tumors In Vivo
Stanford, M. M., Shaban, M., Barrett, J. W., Werden, S. J., Gilbert, P.-A., Bondy-Denomy, J., MacKenzie, L. T., Graham, K. C., Chambers, A. F., & McFadden, G. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300348 · Cited by 80
Cully, M., & Downward, J. (2008) · Cell · doi:10.1016/j.cell.2008.06.020 · Cited by 80
PTEN expression is a strong predictor of survival in mesothelioma patients☆
Opitz, I., Soltermann, A., Abaecherli, M., Hinterberger, M., Probst-Hensch, N., Stahel, R., Moch, H., & Weder, W. (2008) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2007.09.045 · Cited by 82
“PTEN inactivation is probably the most common [20,21] as well as the most potent lesion of the oncogenic phosphatidylinositol-kinase (PI3K) signalling pathway, which has been implicated in nearly all aspects of tumour biology: cell transformation, growth, proliferation, migration, protection, apoptosis, genomic instab…”
BackgroundPI3K/Akt promotes feedforward mTORC2 activation through IKKα
Dan, H. C., Antonia, R. J., & Baldwin, A. S. (2016) · Oncotarget · doi:10.18632/oncotarget.8383 · Cited by 91
Selective Raf inhibition in cancer therapy
Khazak, V., Astsaturov, I., Serebriiskii, I. G., & Golemis, E. A. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.12.1587 · Cited by 78
“Although Ras has other important direct effectors in tumor promotion, including phosphoinositol 3-kinase and RalGDS ( [11,12] and reviewed in [13] ), the Raf > MEK > ERK signaling axis is essential for oncogenesis, based on validation in many systems [14] .”
BackgroundJia, Y., Subramanian, K. K., Erneux, C., Pouillon, V., Hattori, H., Jo, H., You, J., Zhu, D., Schurmans, S., & Luo, H. R. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.016 · Cited by 86
Li, L., Li, J., Wang, Q., Zhao, X., Yang, D., Niu, L., Yang, Y., Zheng, X., Hu, L., & Li, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00815 · Cited by 80
“Several evidences support a protective role of PI3K/Akt signaling pathway in DOX-induced cardiac dysfunction (Shaw and Cantley, 2006; Hu et al., 2019).”
BackgroundMitochondrial immune regulation and anti-tumor immunotherapy strategies targeting mitochondria
Bai, R., & Cui, J. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216223 · Cited by 90
Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma
Pópulo, H., Soares, P., Rocha, A. S., Silva, P., & Lopes, J. M. (2010) · Melanoma Research · doi:10.1097/cmr.0b013e32832ccd09 · Cited by 84
Cheng, Y., Qiu, F., Ye, Y., Tashiro, S., Onodera, S., & Ikejima, T. (2009) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2009.08.011 · Cited by 79
Cortés-Sempere, M., Miguel, M. P. D., Pernía, O., Rodríguez‐Antolín, C., de Castro, J., Nistal, M., Conde, E., López‐Ríos, F., Belda-Iniesta, C., Perona, R., et al. (2012) · Oncogene · doi:10.1038/onc.2012.146 · Cited by 79
Yamauchi, K., Sakurai, H., Kimura, T., Wiriyasermkul, P., Nagamori, S., Kanai, Y., & Kohno, N. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.10.035 · Cited by 79
Choi, E. J., Ryu, Y. K., Kim, S. Y., Wu, H. G., Js, K., Kim, I. H., & Kim, I. A. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0507 · Cited by 82
“mTOR inhibitors can effectively block growth and survival signals by inactivating downstream effectors such as p70 and 4E-binding protein 1 (32, 33).”
BackgroundERK2 Phosphorylates PFAS to Mediate Posttranslational Control of De Novo Purine Synthesis
Ali, E. S., Sahu, U., Villa, E., O’Hara, B. P., Gao, P., Beaudet, C., Wood, A. W., Asara, J. M., & Ben‐Sahra, I. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.001 · Cited by 81
“The importance of closely linking ERK signaling to metabolism control is highlighted by the fact that aberrant regulation of this signaling pathway and cellular metabolism have been implicated in the pathophysiology of a diverse set of human diseases, including cancer and metabolic disorders (DeBerardinis and Chandel,…”
BackgroundDüzgün, Z., Eroğlu, Z., & Avcı, Ç. B. (2015) · Gene · doi:10.1016/j.gene.2015.08.060 · Cited by 89
Jin, N. Y., Jiang, T., Rosen, D. M., Nelkin, B. D., & Ball, D. W. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0662 · Cited by 78
Zou, M., Lu, N., Chen, H., Liu, W., Sun, Y., Wang, X., You, Q., Gu, C., Xi, T., & Guo, Q. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.04.009 · Cited by 79
Inhibition of the Ras-Net (Elk-3) Pathway by a Novel Pyrazole that Affects Microtubules
Wasylyk, C., Zheng, H., Castell, C., Debüssche, L., Multon, M.-C., & Wasylyk, B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2674 · Cited by 82
Alkylphospholipids: An update on molecular mechanisms and clinical relevance
Ríos‐Marco, P., Marco, C., Gálvez, X., Jiménez‐López, J. M., & Carrasco, M. P. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.02.016 · Cited by 90
The Hypoxic Tumour Microenvironment, Patient Selection and Hypoxia-modifying Treatments
Hoogsteen, I. J., Marres, H. A. M., van der Kogel, A. J., & Kaanders, J. H. A. M. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.03.001 · Cited by 90
Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis
Rho, O., Kim, D. J., Kiguchi, K., & DiGiovanni, J. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20665 · Cited by 84
“PTEN, a lipid phosphatase that acts as a tumor suppressor can reverse this phosphorylation reaction [160–162].”
BackgroundRibas, R., Pancholi, S., Guest, S. K., Marangoni, E., Gao, Q., Thuleau, A., Simigdala, N., Polanska, U. M., Campbell, H., Rani, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0143 · Cited by 87
Sanli, T., Liu, C., Rashid, A., Hopmans, S., Tsiani, E., Schultz, C., Farrell, T. J., Singh, G., Wright, J. R., & Tsakiridis, T. K. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182049d8b · Cited by 82
Targeted therapy in GIST: in silico modeling for prediction of resistance
Pierotti, M. A., Tamborini, E., Negri, T., Pricl, S., & Pilotti, S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.3 · Cited by 76
“and RAS/RAF/MEK/MAPK can occur, both converging on mTOR”
BackgroundDavies, B. R., Guan, N., Logié, A., Crafter, C., Hanson, L. L., Jacobs, V. N., James, N. H., Dudley, P., Jacques, K., Ladd, B., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0230 · Cited by 76
“Increased localization of FOXO3a to the nucleus is consistent with inhibition of FOXO3a phosphorylation by AKT, which enables FOXO3a to switch on the expression of genes such as p27, FasL, andBIM,which collectively induce cell-cycle arrest and/ or apoptosis (1, 2, 19).”
Background
Metadata
- Authors
- Shaw, R. J., & Cantley, L. C.
- Affiliations
- Salk Institute for Biological Studies (US)
- Beth Israel Deaconess Medical Center (US)
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 424-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2144323242
- Cited by
- 2,019
- References
- 86
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 48 · 2023: 68 · 2022: 68 · 2021: 77 · 2020: 91 · 2019: 74 · 2018: 95 · 2017: 99 · 2016: 109 · 2015: 146 · 2014: 119 · 2013: 153 · 2012: 143
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041890)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- Ras signaling, PI3K signaling, mTOR signaling, tumour cell growth, nutrient sensing, amino acids, glucose, oxygen availability, cancer mutations, carcinogenesis, cell survival
- MeSH terms
- Animals, Humans, Neoplasms, Protein Kinases, Signal Transduction, ras Proteins, Phosphatidylinositol 3-Kinases, Cell Growth Processes, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.